EMERYVILLE, Calif. and NEW YORK—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a developer of eyecare, skin care and wound care products, and Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, have commenced co-promotion activities under an agreement that was first announced in March. Under the agreement, Eyenovia is leveraging its 10-person field sales force to promote NovaBay’s Avenova Antimicrobial Lid & Lash solution to large ophthalmic surgery centers, along with Eyenovia's own FDA-approved MydCombi for mydriasis, NovaBay announced.

In parallel, NovaBay said that it has initiated reconnaissance and market preparation activities ahead of Eyenovia’s launch of clobetasol propionate ophthalmic suspension, 0.05%, a rapid, sustained solution for the treatment of postoperative inflammation and pain. Clobetasol is expected to be commercially available in August 2024, according to the announcement. 

“We are excited the Eyenovia team is now selling prescription Avenova and look forward to offering clobetasol as a complementary product to our nationwide established network of thousands of eyecare professionals,” said Justin Hall, CEO of NovaBay. “This partnership is a cost-efficient means of generating greater awareness among eyecare professionals for both companies’ products and provides an opportunity for us to further build our physician-dispensed channel by promoting the first new ophthalmic steroid to enter the U.S. market in more than 15 years.”

“Avenova is long established as the leading doctor-recommended hypochlorous-based lid and lash spray, making it ideal for our highly differentiated prescription ophthalmic product portfolio,” stated Michael Rowe, CEO of Eyenovia. “We are delighted to offer this complementary, high-quality product through our sales team and to strengthen relationships with eyecare professionals prior to clobetasol’s launch later this summer.”

Prescription Avenova is available through EyenoviaRx.com and at https://avenova.com/pages/rx-preview. The non-prescription product is available directly to consumers through Amazon and other retailers.